# US 2013/0158266 A1 · (2R)-1-(3-Chloro-2-Pyrazinyl)-2-Methylpiperazine And Salts Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158266 A1
- Document ID: US20130158266A1
- Status: Published application
- Kind: A1
- Application number: 13/768,641
- Filed: 2013-02-15
- Published: 2013-06-20
- Earliest claimed: 2002-06-19
- Assignees: Biovitrum AB (publ.)
- Inventors: Tom Fleck; Magnus Cernerud; Helena Lundstrom; Claes Lofstrom; Margit Pelcman; Alexander Paptchikhine; Emma Andersson; Alf Nygren
- Web page: https://patentgrep.com/patent/US20130158266A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/00: Drugs for disorders of the nervous system
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. In one aspect, the invention relates to a process for the preparation of compounds of the general formula (I): wherein HA is a pharmaceutically acceptable acid and R1-R4 are each independently selected from the group consisting of hydrogen, halogen, C1-C6-alkyl, C1-C6-alkoxy, and di-C1-C6-alkylamino-C2-C6-alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.

## Claims

### Claim 1

A process for the preparation of the general formula (I):
comprising the steps of:
(i) O-alkylating a 3-pyridinol derivative of the general formula (II) or the corresponding hydrochloride:
to give another 3-pyridinol derivative of the general formula (III):
(ii) reacting the 3-pyridinol derivative of the general formula (III) with (2R)-1-(3-chloro-2-pyrazinyl)-2-methylpyrazine of the formula (IV) in the presence of the alkali metal tert-butoxide or an alkali metal tert-butoxide.
to give a compound of the general formula (V):
(iii) converting the compound of the general formula (V) to the compound of the general formula (I) by treatment with a pharmaceutically acceptable acid of the formula HA,
wherein each of R1, R2, R3, and R4, independently, is hydrogen, C1-C6-alkyl, C1-C6-alkoxy, and di-C1-C6-alkylamino-C2-C6alkoxy.

### Claim at position 2

2-34. (canceled)
